Oct 14 (Reuters) - Australian biotech CSL (CSL.AX) said connected Thursday it was committed to its statement for the accumulation of astir 50 cardinal doses of AstraZeneca's (AZN.L) COVID-19 vaccine into 2022.
The announcement came aft a media study said the British drugmaker's vaccine, Vaxzevria, volition nary longer beryllium manufactured successful Australia owed to request for vaccines of Pfizer (PFE.N) and Moderna (MRNA.O). [nL4N2R91XR]
Pfizer and Moderna person established a marketplace dominance by utilizing mRNA-based COVID-19 vaccine exertion to combat the pandemic.
CSL, successful a brief statement, added that much than 20 cardinal of the doses person already been produced, and it is expected that the remaining accumulation volition beryllium completed aboriginal adjacent year.
Cafes, gyms and restaurants successful Sydney welcomed backmost afloat vaccinated customers earlier this week aft astir 4 months of a lockdown, arsenic Australia aims to statesman surviving with the coronavirus and gradually reopen with precocious rates of inoculation.
Reporting by Indranil Sarkar successful Bengaluru; Editing by Maju Samuel
Our Standards: The Thomson Reuters Trust Principles.